Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation

Journal of Surgical Research

Volumn 128, Issue 1, 2005, Pages 140-146

  Yang, Shung Haur ^a,b   Lin, Jen Kou ^b   Huang, Chi Jung ^c   Chen, Wei Shone ^b   Li, Shih Yun ^b   Chiu, Jen Hwey ^a,b,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d CHENG HSIN REHABILITATION MEDICAL CENTER   (Taiwan)

Author keywords

Angiogenesis; Colon cancer; Flt 1; KDR; Silymarin silibinin; VEGF; VEGFR

Indexed keywords

MESSENGER RNA; SILIBININ; SILYMARIN; THALIDOMIDE; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; ASSAY; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITY; DRUG EFFECT; DRUG EXPOSURE; EMBRYO; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ANGIOGENESIS INHIBITORS; CELL LINE; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; SILYMARIN; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 23944519382     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2005.04.042     Document Type: Article

References (38)

1. P. Ferenci, B. Dragosics, H. Dittrich Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver J. Hepatol. 9 1989 105
2. K. Flora, M. Hahn, H. Rosen, K. Benner Milk thistle (Silybum marianum) for the therapy of liver disease Am. J. Gastroenterol. 93 1998 139
3. C. Gerhauser, K. Klimo, E. Heiss Mechanism-based in vitro screening of potential cancer chemopreventive agents Mutat. Res. 524 2003 163
4. S.K. Katiyar, N.J. Korman, H. Mukhtar, R. Agarwal Protective effects of silymarin against photocarcinogenesis in a mouse skin model J. Natl. Cancer I. 89 1997 556
5. G. Sharma, R.P. Singh, D.C. Chan, R. Agarwal Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells Anticancer Res. 23 2003 2649
6. X. Zi, A.W. Grasso, H.J. Kung, R. Agarwal A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells Cancer Res. 58 1998 1920
7. N. Ahmad, H. Gali, S. Javed, R. Agarwal Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression Biochem. Bioph. Res. Co. 247 1998 294
8. S.K. Manna, A. Mukhopadhyay, N.T. Van, B.B. Aggarwal Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis J. Immunol. 163 1999 6800
9. C. Agarwal, R.P. Singh, S. Dhanalakshmi Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells Oncogene 22 2003 8271
10. A.K. Tyagi, C. Agarwal, R.P. Singh, K.R. Shroyer, L.M. Glode, R. Agarwal Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells Biochem. Bioph. Res. Co. 312 2003 1178
11. H.G. Yoo, S.N. Jung, Y.S. Hwang Involvement of NF-kappaB and caspases in silibinin-induced apoptosis of endothelial cells Int. J. Mol. Med. 13 2004 81
12. C. Jiang, R. Agarwal, J. Lu Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells Biochem. Bioph. Res. Co. 276 2000 371
13. S.H. Yang, J.K. Lin, W.S. Chen, J.H. Chiu Anti-angiogenic effect of silymarin on colon cancer LoVo cell line J. Surg. Res. 113 2003 133
14. N. Ferrara Vascular endothelial growth factor Basic science and clinical progress Endocr. Rev. 25 2004 581
15. C.J. Edgell, C.C. McDonald, J.B. Graham Permanent cell line expressing human factor VIII-related antigen established by hybridization Proc. Natl. Acad. Sci. U.S.A. 80 1983 3734
16. M. Hidalgo, A.S. Pierson, S.N. Holden, M. Bergen, S.G. Eckhardt Therapeutic angiogenesis inhibitors in the treatment of cancer Adv. Internal Med. 47 2001 159
17. D.H. Ausprunk, D.R. Knighton, J. Folkman Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels Acta Haematol. 79 1975 597
18. Y. Sharma, C. Agarwal, A.K. Singh, R. Agarwal Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells Mol. Carcinogen. 30 2001 224
19. J. Folkman Tumor angiogenesis Therapeutic implications N. Engl. J. Med. 285 1971 1182
20. G.D. Yancopoulos, S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand, J. Holash Vascular-specific growth factors and blood vessel formation Nature 407 2000 242
21. G. Neufeld, T. Cohen, S. Gengrinovitch, Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors FASEB J. 13 1999 9
22. X. Tian, S. Song, J. Wu, L. Meng, Z. Dong, C. Shou Vascular endothelial growth factor Acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803 Biochem. Bioph. Res. Co. 286 2001 505
23. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335
24. G. Hahn, H.D. Lehmann, M. Kurten, H. Uebel, G. Vogel [On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from Silybum marianum (L.) Gaertn] Arzneimittel-Forschung 18 1968 698
25. C. de Vries, J.A. Escobedo, H. Ueno, K. Houck, N. Ferrara, L.T. Williams The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor Science 255 1992 989
26. J.B. Kearney, N.C. Kappas, C. Ellerstrom, F.W. DiPaola, V.L. Bautch The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis Blood 103 2004 4527
27. J.B. Kearney, C.A. Ambler, K.A. Monaco, N. Johnson, R.G. Rapoport, V.L. Bautch Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division Blood 99 2002 2397
28. C. Herold-Mende, H.H. Steiner, T. Andl Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells Lab. Invest. 79 1999 1573
29. S. Hiratsuka, O. Minowa, J. Kuno, T. Noda, M. Shibuya Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice Proc. Natl. Acad. Sci. U.S.A. 95 1998 9349
30. M. Shibuya, L. Seetharam, Y. Ishii Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis Princess Takamatsu Symposia 24 1994 162
31. G.H. Fong, J. Rossant, M. Gertsenstein, M.L. Breitman Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium Nature 376 1995 66
32. N. Ferrara, T. Davis-Smyth The biology of vascular endothelial growth factor Endocr. Rev. 18 1997 4
33. J.E. Park, H.H. Chen, J. Winer, K.A. Houck, N. Ferrara Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR J. Biol. Chem. 269 1994 25646
34. R.L. Kendall, G. Wang, K.A. Thomas Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR Biochem. Bioph. Res. Co. 226 1996 324
35. H.P. Gerber, F. Condorelli, J. Park, N. Ferrara Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia J. Biol. Chem. 272 1997 23659
36. C. Hornig, B. Barleon, S. Ahmad, P. Vuorela, A. Ahmed, H.A. Weich Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids Lab. Invest. 80 2000 443
37. D. Gallo, S. Giacomelli, C. Ferlini Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer Eur. J. Cancer 39 2003 2403
38. I. Kim, J.H. Kim, Y.S. Ryu, S.H. Jung, J.J. Nah, G.Y. Koh Characterization and expression of a novel alternatively spliced human angiopoietin-2 J. Biol. Chem. 275 2000 18550